Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.

Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.

Children with Down syndrome (DS) up to the age of 4 years are at a 150-fold excess risk of developing myeloid leukemia (ML-DS). Approximately 4%-5% of newborns with DS develop transient myeloproliferative disorder (TMD). Blast cell structure and immunophenotype are similar in TMD and ML-DS. A mutati...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Alford, K, Reinhardt, K, Garnett, C, Norton, A, Böhmer, K, von Neuhoff, C, Kolenova, A, Marchi, E, Klusmann, J, Roberts, I, Hasle, H, Reinhardt, D, Vyas, P
Format:	Journal article
Sprache:	English
Veröffentlicht:	2011

Ähnliche Einträge

GATA1 Mutation In Transient Leukemia (TL) and Myeloid Leukemia of Down Syndrome
von: Reinhardt, K, et al.
Veröffentlicht: (2010)

GATA1 Mutation In Transient Leukemia (TL) and Myeloid Leukemia of Down Syndrome
von: Reinhardt, K, et al.
Veröffentlicht: (2010)

GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia
von: Maroz, A, et al.
Veröffentlicht: (2014)

GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.
von: Maroz, A, et al.
Veröffentlicht: (2014)

GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome
von: Garnett, C, et al.
Veröffentlicht: (2019)

Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
von: Roy, A, et al.
Veröffentlicht: (2009)

Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
von: Norton, A, et al.
Veröffentlicht: (2007)

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML.
von: Hasle, H, et al.
Veröffentlicht: (2008)

GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
von: Carpenter, E, et al.
Veröffentlicht: (2005)

JAK mutations in Down syndrome - associated transient myeloproliferative disorder and acute megakaryocytic leukemia
von: Vyas, P, et al.
Veröffentlicht: (2008)

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study
von: Marius Flasinski, et al.
Veröffentlicht: (2018-07-01)

Transient myeloproliferative disorder in Down′s syndrome
von: Vinayak Y Kshirsagar, et al.
Veröffentlicht: (2012-01-01)

Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome
von: Labuhn, M, et al.
Veröffentlicht: (2019)

GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with down syndrome; implications for leukemogenesis.
von: Hellebostad, M, et al.
Veröffentlicht: (2005)

Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.
von: Tunstall-Pedoe, O, et al.
Veröffentlicht: (2008)

Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
von: Heald, B, et al.
Veröffentlicht: (2007)

DNMT3A mutations are rare in childhood acute myeloid leukemia
von: Felicitas Thol, et al.
Veröffentlicht: (2011-08-01)

Transient Myeloproliferative Disorder and Down Syndrome Is there a link?
von: Zenaida S. Reyes, et al.
Veröffentlicht: (2012-11-01)

Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
von: Eline J.M. Bertrums, et al.
Veröffentlicht: (2021-12-01)

Acute leukemias in children with Down syndrome.
von: Zwaan, C, et al.
Veröffentlicht: (2010)

How do Gata1 and cohesin gene mutations contribute to the development of myeloid leukaemia?
von: Garnett, C
Veröffentlicht: (2020)

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome
von: Cruz Hernandez, D, et al.
Veröffentlicht: (2020)

GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.
von: Roberts, I, et al.
Veröffentlicht: (2013)

Analysis of GATA-1 mutations in chronic myeloid leukaemia.
von: Halsey, C, et al.
Veröffentlicht: (2006)

Acute leukemias in children with Down syndrome.
von: Zwaan, M, et al.
Veröffentlicht: (2008)

Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease
von: Marjolein Blink, et al.
Veröffentlicht: (2012-04-01)

GATA1 mutational analysis in chronic myeloid leukaemia.
von: Halsey, C, et al.
Veröffentlicht: (2007)

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia
von: Anand A. Patel, et al.
Veröffentlicht: (2024-10-01)

Natural history of GATA-1 mutations in Down syndrome.
von: Ahmed, M, et al.
Veröffentlicht: (2003)

Myeloid pre-leukemia and leukemia of Down syndrome
von: Cruz Hernandez, D, et al.
Veröffentlicht: (2020)

Natural history of GATA1 mutations in Down syndrome.
von: Ahmed, M, et al.
Veröffentlicht: (2004)

Modelling the progression of a preleukemic stage to overt leukemia in children with down syndrome
von: Labuhn, M, et al.
Veröffentlicht: (2018)

Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study
von: Marjolein Blink, et al.
Veröffentlicht: (2014-02-01)

Impact of mutant haemopoietic transcription factor GATA1s on haemopoiesis
von: Vyas, P, et al.
Veröffentlicht: (2017)

Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome
von: Tunstall, O, et al.
Veröffentlicht: (2018)

Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia
von: Anne Kresinsky, et al.
Veröffentlicht: (2018-11-01)

GATA2 mutations and overexpression in pediatric acute myeloid leukemia
von: Zhenzhen Yang, et al.
Veröffentlicht: (2019-08-01)

RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
von: Tim Kong, et al.
Veröffentlicht: (2025-01-01)

Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation
von: Steven Wang, et al.
Veröffentlicht: (2016-01-01)

Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
von: Vyas, P, et al.
Veröffentlicht: (2006)